Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish
Earlier this month, Biohaven reported achieving important milestones in the trial of its experimental drug BHV-1300, which is intended for use in the treatment of kidney disease. First Published Dec 31, 2024, 10:21 PM IST | Last Updated Dec 31, 2024, 10:21 …